Ariel - Volume 11 Number 6

Executive Editors Ellen Feldman Leonardo S. Nasca, Jr. Business Managers Alex Macones Martin B. Getzow News Editor Hugh A. Gelabert Features Editor Aaron D. Bleznak CAHS Editor Joan M. Greco Editorial Page Editor Samuel Markind Photography Editor Todd L. Demmy Sports Editor Paul F. Mansfield Commons Editor Saul I. Helfin

Ariel - Volume 12(13) Number 1

Executive Editor Gary E. Fishbein Associate Editor Sam Markind Business Manager Rich Davis Sports Editor Dave Cohen Photography Editor Ben Alman Layout Sheila Grossma

Ariel - Volume 11 Number 4

Executive Editor Ellen Feldman Leonardo S. Nasca, Jr. Business Managers Barbara L. Davies Martin B. Getzow News Editor Hugh A. Gelabert Features Editor Aaron D. Bleznak CAHS Editor Joan M. Greco Editorial Page Editor Samuel Markind Photography Editor Todd L. Demmy Sports Editor Paul F. Mansfiel

Boric Acid Reclamation System (BARS)

KLM Technologies' personnel have identified a Boric Acid Reclamation System (BARS) utilizing reverse osmosis and ultrafiltration to produce a recyclable grade of otherwise waste boric acid at PWRs, thus reducing a major source of low-level radwaste. The design of a prototype BARS as a compact volume reduction system was the result of KLM's Phase 1 Program, and based upon a preliminary feasibility program, which assessed the applicability of membrane technology to refurbish and recycle waste boric acid from floor and equipment drain streams. The analysis of the overall program indicated a substantial savings regarding off-site disposal costs. Today's economic scenario indicates that optimization of volume reduction operation procedures could significantly reduce waste management costs, especially where burial penalties have become more severe. As a reaction to the economic burden imposed by final disposal, many nuclear plants are currently modifying their design and operating philosophies concerning liquid radwaste processing systems to meet stricter environmental regulations, and to derive potential economic benefits by reducing the ever-increasing volumes of wastes that are produced. To effect these changes, innovative practices in waste management and more efficient processing technologies are being successfully implemented

Ariel - Volume 11 Number 3

Executive Editors Ellen Feldman Leonardo S. Nasca, Jr. Business Managers Barbara L. Davies Martin B. Getzow News Editor Hugh A. Gelabert Features Editor Aaron D. Bleznak CAHS Editor Joan M. Greco Editorial Page Editor Samuel Markind Photography Editor Todd Demmy Sports Editor Paul F. Mansfiel

Ariel - Volume 11 Number 1

Executive Editors Ellen Feldman Leonardo S. Nasca, Jr. Business Managers Barbara L. Davies Martin B. Getzow News Editor Aaron D. Bleznak Features Editor Dave Van Wagoner CAHS Editor Joan M. Greco Editorial Page Editor Samuel Markind Photography Editor Leonardo S. Nasca, Jr. Sports Editor Paul F. Mansfiel

Long-term Effectiveness and Tolerability of Topiramate in Children with Epilepsy under the Age of 2 Years: 4-Year Follow-up

This is a long-term, open label, observational study aimed to broaden our clinical experiences in managing infants and toddlers with epilepsy. The long-term retention rate and side effects of topiramate (TPM) in them were evaluated and compared with carbamazepine (CBZ). A total of 146 children were involved in the study (TPM=41, CBZ=105). The retention rates at 24 , 36, and 48 months were 46.3%, 34.1%, 26.8% for TPM and 36.2%, 23.8%, 13.3% for CBZ, respectively. At 6 months after starting antiepileptic drugs (AED), the seizure freedom or clinical efficacy (seizure reduction rate more than 50 percent) were 73.2% for TPM and 62.9% for CBZ. The major side effects led to discontinuation included psychomotor slowing, poor oral intake from TPM and sleepiness and skin rash from CBZ. TPM was discontinued due to side effects in one case (2.4%) and lack of efficacy in five cases (12.2%), whereas CBZ was discontinued due to lack of efficacy (22.9%) and side effects (6.7%). As compared with CBZ, TPM showed the same long-term retention rate in children under the age of 2 yr, and no serious side effects. It is therefore concluded that TPM can be considered as a major AED for treating children with epilepsy under the age of 2 yr